Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA
Press release content from PR Newswire. The AP news staff was not involved in its creation. Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA January 27, 2021 GMT INCHEON, South Korea, Jan. 26, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company’s track record as a premiere CDO service provider in the global market. In late 2018, National OncoVenture (NOV), a government-funded virtual ...
Source: apnews.com